Loading...
•
Dec 31, 2021
Ultragenyx Q4 2021 Earnings Report
Ultragenyx reported Q4 2021 financial results and provided a corporate update.
Key Takeaways
Ultragenyx reported a total revenue of $83.4 million for Q4 2021. The company made significant progress across its early and late-stage clinical pipeline and is preparing for the launch of Evkeeza in Europe.
Total revenue for Q4 2021 was $83.4 million.
Crysvita revenue in Ultragenyx territories was $55.5 million, including $50.2 million in collaboration revenue in the North American profit share territory.
Dojolvi product sales were $11.8 million.
The company had a cash balance of approximately $1.0 billion at the end of 2021.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Ultragenyx expects 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million and Dojolvi revenue to be between $55 million and $65 million.
Positive Outlook
- 2022 revenue for Crysvita in Ultragenyx territories to be between $250 million and $260 million.
- Dojolvi revenue to be between $55 million and $65 million.
- Submission of reimbursement dossiers expected in European countries in 2022 for Evkeeza.
- Dosing in the Pivotal Phase 2/3 Orbit study for UX143 is expected to begin in the first half of 2022.
- Phase 3 eNH3ance study of DTX301 expected to initiate in first half of 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...